Roth Capital Predicts biote’s Q4 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD) – Equities researchers at Roth Capital dropped their Q4 2024 EPS estimates for biote in a note issued to investors on Wednesday, November 13th. Roth Capital analyst G. Kelly now expects that the company will post earnings per share of $0.13 for the quarter, down from their previous forecast of $0.19. The consensus estimate for biote’s current full-year earnings is $0.53 per share. Roth Capital also issued estimates for biote’s Q1 2025 earnings at $0.13 EPS, Q2 2025 earnings at $0.16 EPS, Q3 2025 earnings at $0.18 EPS, Q4 2025 earnings at $0.20 EPS and FY2025 earnings at $0.67 EPS.

biote Trading Up 21.7 %

Shares of NASDAQ BTMD opened at $6.72 on Thursday. The company has a 50-day moving average of $5.53 and a 200 day moving average of $6.28. biote has a 12-month low of $3.65 and a 12-month high of $8.44. The stock has a market cap of $364.36 million, a PE ratio of 25.85 and a beta of 0.94.

biote (NASDAQ:BTMD) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $0.33 EPS for the quarter, topping the consensus estimate of $0.09 by $0.24. The company had revenue of $51.38 million during the quarter, compared to analyst estimates of $51.38 million. biote had a negative return on equity of 38.13% and a net margin of 5.20%.

Institutional Investors Weigh In On biote

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its holdings in shares of biote by 1,016.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 660,069 shares of the company’s stock valued at $4,931,000 after acquiring an additional 600,956 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of biote by 251.8% in the 2nd quarter. Renaissance Technologies LLC now owns 193,077 shares of the company’s stock valued at $1,442,000 after buying an additional 138,200 shares during the last quarter. Sanders Morris Harris LLC raised its stake in biote by 131.2% during the 3rd quarter. Sanders Morris Harris LLC now owns 180,965 shares of the company’s stock worth $1,010,000 after acquiring an additional 102,706 shares in the last quarter. GDS Wealth Management purchased a new stake in biote in the second quarter valued at $432,000. Finally, Skylands Capital LLC boosted its stake in biote by 36.2% in the second quarter. Skylands Capital LLC now owns 160,845 shares of the company’s stock valued at $1,202,000 after acquiring an additional 42,729 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.